

## REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH POST-MYOCARDIAL INFARCTION

1. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P: **Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.** *European heart journal* 2016.
2. National Institute for Health and Care Excellence: **Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease [CG 172].** In: *Clinical Guideline.* UK: NICE; 2013.
3. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S *et al*: **Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.** *New England Journal of Medicine* 2017, **0(0)**:null.
4. Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S *et al*: **Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.** *The Canadian journal of cardiology* 2013, **29(11)**:1334-1345.
5. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L *et al*: **2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.** *Circulation* 2016, **134(10)**:e123-155.
6. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H *et al*: **Ticagrelor versus clopidogrel in patients with acute coronary syndromes.** *The New England journal of medicine* 2009, **361(11)**:1045-1057.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA *et al*: **Prasugrel versus clopidogrel in patients with acute coronary syndromes.** *The New England journal of medicine* 2007, **357(20)**:2001-2015.
8. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM *et al*: **Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.** *The New England journal of medicine* 2005, **352(12)**:1179-1189.
9. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS: **Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.** *Lancet (London, England)* 2005, **366(9497)**:1607-1621.
10. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, Lenarz LA: **Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.** *Journal of the American College of Cardiology* 2012, **60(5)**:388-396.

11. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK *et al*: **Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.** *Journal of the American College of Cardiology* 2011, **57**(6):672-684.
12. Varenhorst C, Alstrom U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC *et al*: **Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.** *Journal of the American College of Cardiology* 2012, **60**(17):1623-1630.
13. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F *et al*: **Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.** *The New England journal of medicine* 2012, **367**(14):1297-1309.
14. Mancini GBJ, Gosselin G, Chow B, Kostuk W, Stone J, Yvorchuk KJ, Abramson BL, Cartier R, Huckell V, Tardif J-C *et al*: **Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease.** *Canadian Journal of Cardiology*, **30**(8):837-849.
15. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA *et al*: **2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.** *Circulation* 2013, **127**(4):529-555.
16. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes DR, Jr., Jaffe AS, Jneid H, Kelly RF, Kontos MC *et al*: **2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *Circulation* 2014, **130**(25):2354-2394.
17. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F *et al*: **ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.** *European heart journal* 2012, **33**(20):2569-2619.
18. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP *et al*: **2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).** *European heart journal* 2016, **37**(3):267-315.
19. Dargie HJ: **Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.** *Lancet (London, England)* 2001, **357**(9266):1385-1390.
20. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS: **Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.** *Lancet (London, England)* 2005, **366**(9497):1622-1632.
21. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Jr., Grover S, Gupta M *et al*: **2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.** *The Canadian journal of cardiology* 2016, **32**(11):1263-1282.

22. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME *et al*: **2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.** *Journal of the American College of Cardiology* 2014, **64**(21):e1-76.
23. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM *et al*: **Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.** *Lancet (London, England)* 2013, **381**(9872):1107-1115.
24. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C: **The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.** *Lancet (London, England)* 2012, **380**(9841):581-590.
25. National Institute for Health and Care Excellence: **Cardiovascular disease: risk assessment and reduction, including lipid modification.** In: *NICE Guideline*. UK; 2014.
26. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P *et al*: **ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).** *European heart journal* 2011, **32**(14):1769-1818.
27. Silberman S, Neukirch-Stoop C, Steg PG: **Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting.** *The American journal of cardiology* 2005, **95**(4):509-510.
28. Page NA, Schroeder WS: **Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy.** *The Annals of pharmacotherapy* 2007, **41**(1):61-67.
29. Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, Mihalcsik L, Gavazzi A: **Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation.** *The American journal of cardiology* 2008, **101**(6):786-789.
30. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet (London, England)* 1996, **348**(9038):1329-1339.
31. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: **Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.** *The New England journal of medicine* 2003, **348**(14):1309-1321.
32. Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW *et al*: **AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.** *Circulation* 2011, **124**(22):2458-2473.

33. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. *Lancet (London, England)* 1986, **2**(8498):57-66.
34. Freemantle N, Cleland J, Young P, Mason J, Harrison J: **beta Blockade after myocardial infarction: systematic review and meta regression analysis**. *BMJ (Clinical research ed)* 1999, **318**(7200):1730-1737.
35. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *Jama* 1982, **247**(12):1707-1714.
36. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. *The New England journal of medicine* 1981, **304**(14):801-807.
37. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F *et al*: **Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial**. *Lancet (London, England)* 1981, **2**(8251):823-827.
38. Helfand M PK, Christensen V: **Drug class review- Beta adrenergic blockers**. In., vol. Update 4. Portland, Oregon: Oregon Health & Science University; 2009.
39. Boissel JP, Leizorovicz A, Picolet H, Ducruet T: **Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators**. *The American journal of cardiology* 1990, **66**(9):24C-31C.
40. Hansteen V, Moinichen E, Lorentsen E, Andersen A, Strom O, Soiland K, Dyrbekk D, Refsum AM, Tromsdal A, Knudsen K *et al*: **One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial**. *British medical journal (Clinical research ed)* 1982, **284**(6310):155-160.
41. Salathia KS, Barber JM, McIlmoyle EL, Nicholas J, Evans AE, Elwood JH, Cran G, Shanks RG, Boyle DM: **Very early intervention with metoprolol in suspected acute myocardial infarction**. *European heart journal* 1985, **6**(3):190-198.
42. Perez MI, Musini VM, Wright JM: **Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event**. *The Cochrane database of systematic reviews* 2009(4):CD006743.
43. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U *et al*: **beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease**. *Jama* 2012, **308**(13):1340-1349.
44. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, DiNicolantonio JJ, Devereaux PJ, Alexander KP, Wetterslev J *et al*: **Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials**. *The American journal of medicine* 2014, **127**(10):939-953.
45. Ibáñez B, Raposeiras-Roubin S, García-Ruiz JM: **The Swing of  $\beta$ -Blockers: Time for a System Reboot\***. *Journal of the American College of Cardiology* 2017, **69**(22):2721-2724.
46. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, Smith SC, Jr., Subacius H: **Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction**. *Journal of the American College of Cardiology* 2015, **66**(13):1431-1441.

47. Choo EH, Chang K, Ahn Y, Jeon DS, Lee JM, Kim DB, Her SH, Park CS, Kim HY, Yoo KD *et al*: **Benefit of beta-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention**. *Heart (British Cardiac Society)* 2014, **100**(6):492-499.
48. Raposeiras-Roubin S, Abu-Assi E, Redondo-Dieguez A, Gonzalez-Ferreiro R, Lopez-Lopez A, Bouzas-Cruz N, Castineira-Busto M, Pena Gil C, Garcia-Acuna JM, Gonzalez-Juanatey JR: **Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today?** *Revista espanola de cardiologia (English ed)* 2015, **68**(7):585-591.
49. Yang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, Kim JH, Ahn YK, Jeong MH, Choi DJ *et al*: **Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention**. *JACC Cardiovascular interventions* 2014, **7**(6):592-601.
50. Puymirat E, Riant E, Aissoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D *et al*: **beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study**. *BMJ (Clinical research ed)* 2016, **354**:i4801.
51. Dickstein K, Kjekshus J: **Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan**. *Lancet (London, England)* 2002, **360**(9335):752-760.
52. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H *et al*: **Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both**. *The New England journal of medicine* 2003, **349**(20):1893-1906.
53. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). *Lancet (London, England)* 1995, **345**(8951):686-687.
54. Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG: **Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials**. *Archives of internal medicine* 2006, **166**(7):787-796.
55. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet (London, England)* 1995, **345**(8951):669-685.
56. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: **Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients**. *The New England journal of medicine* 2000, **342**(3):145-153.
57. Fox KM: **Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)**. *Lancet (London, England)* 2003, **362**(9386):782-788.

58. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: **Telmisartan, ramipril, or both in patients at high risk for vascular events.** *The New England journal of medicine* 2008, **358**(15):1547-1559.
59. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ *et al*: **Statins for acute coronary syndrome.** *The Cochrane database of systematic reviews* 2014(9):CD006870.
60. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: **Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.** *Jama* 2001, **285**(13):1711-1718.
61. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: **Intensive versus moderate lipid lowering with statins after acute coronary syndromes.** *The New England journal of medicine* 2004, **350**(15):1495-1504.
62. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM *et al*: **2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *Circulation* 2014, **129**(25 Suppl 2):S1-45.
63. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *The Lancet* 2006, **367**(9526):1903-1912.
64. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO *et al*: **A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting.** *New England Journal of Medicine* 1998, **339**(23):1665-1671.
65. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M *et al*: **Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome.** *New England Journal of Medicine* 2011, **365**(8):699-708.
66. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L: **Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.** *European heart journal* 2011, **32**(22):2781-2789.
67. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA *et al*: **Rivaroxaban in patients with a recent acute coronary syndrome.** *The New England journal of medicine* 2012, **366**(1):9-19.
68. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Janus J, Burton P, van Eickels M *et al*: **Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.** *The New England journal of medicine* 2016, **375**(25):2423-2434.
69. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA *et al*: **2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.** *Journal of the American College of Cardiology* 2013, **61**(4):e78-140.

70. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK *et al*: **Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation**. *Archives of internal medicine* 2010, **170**(16):1433-1441.
71. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marin F: **Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)**. *European heart journal* 2010, **31**(11):1311-1318.
72. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Jr., Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ: **Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary**. *Circulation Cardiovascular interventions* 2011, **4**(5):522-534.
73. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW *et al*: **Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation**. *Annals of medicine* 2008, **40**(6):428-436.
74. Shoeb M, Fang MC: **Assessing Bleeding Risk in Patients Taking Anticoagulants**. *Journal of thrombosis and thrombolysis* 2013, **35**(3):312-319.
75. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF: **Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients**. *Stroke* 2004, **35**(10):2362-2367.
76. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH *et al*: **Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial**. *Lancet (London, England)* 2010, **376**(9749):1320-1328.
77. Hulot JS, Collet JP, Montalescot G: **Genetic substudy of the PLATO trial**. *Lancet (London, England)* 2011, **377**(9766):637, author reply 637-638.
78. Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K: **Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis**. *Journal of thrombosis and haemostasis : JTH* 2010, **8**(12):2624-2641.
79. Kwok CS, Nijjar RS, Loke YK: **Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis**. *Drug safety* 2011, **34**(1):47-57.
80. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanos A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L *et al*: **Clopidogrel with or without omeprazole in coronary artery disease**. *The New England journal of medicine* 2010, **363**(20):1909-1917.
81. Gerson LB, McMahon D, Olkin I, Stave C, Rockson SG: **Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature**. *Digestive diseases and sciences* 2012, **57**(5):1304-1313.

82. Huang B, Huang Y, Li Y, Yao H, Jing X, Huang H, Li J: **Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis.** *Archives of medical research* 2012, **43**(3):212-224.
83. van Boxel OS, van Oijen MG, Hagens MP, Smout AJ, Siersema PD: **Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study.** *The American journal of gastroenterology* 2010, **105**(11):2430-2436; quiz 2437.
84. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M: **Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.** *Clinical pharmacology and therapeutics* 2011, **89**(1):65-74.
85. Vries MJ, van der Meijden PE, Henskens YM, ten Cate-Hoek AJ, ten Cate H: **Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review.** *Thrombosis and haemostasis* 2016, **115**(1):7-24.
86. Cohen M: **Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.** *Mayo Clinic proceedings* 2009, **84**(2):149-160.
87. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF *et al*: **Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.** *The American journal of cardiology* 2003, **92**(8):930-935.
88. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF *et al*: **Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.** *Jama* 2011, **305**(11):1097-1105.
89. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L *et al*: **ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.** *Journal of the American College of Cardiology* 2010, **56**(24):2051-2066.
90. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M *et al*: **Apixaban with antiplatelet therapy after acute coronary syndrome.** *The New England journal of medicine* 2011, **365**(8):699-708.
91. Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB: **RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.** *European heart journal* 2011, **32**(20):2541-2554.
92. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF *et al*: **Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.** *BMJ (Clinical research ed)* 2011, **342**:d3527.



93. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H *et al*: **Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis** 2010, **122**(21):2131-2141.
94. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: **Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.** *The New England journal of medicine* 2001, **345**(7):494-502.
95. U.S. Food and Drug Administration: **Prasugrel Medical Review.** In: *NDA 022307.* 2009.
96. U.S. Food and Drug Administration: **Ticagrelor Medical Review.** In: *NDA 022433.* 2011.
97. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K *et al*: **Long-term use of ticagrelor in patients with prior myocardial infarction.** *The New England journal of medicine* 2015, **372**(19):1791-1800.
98. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ *et al*: **Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.** *The New England journal of medicine* 2014, **371**(23):2155-2166.
99. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ *et al*: **Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.** *Jama* 2016, **315**(16):1735-1749.
100. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L: **DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.** *Journal of the American College of Cardiology* 2016, **67**(21):2492-2502.
101. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ *et al*: **Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.** *The New England journal of medicine* 2010, **363**(10):930-942.
102. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S: **Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.** *Circulation* 2003, **108**(14):1682-1687.
103. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A *et al*: **Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.** *Lancet (London, England)* 2010, **376**(9748):1233-1243.
104. Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C, Moschovitis A, Windecker S, Valgimigli M: **Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.** *Annals of internal medicine* 2017, **167**(1):17-25.
105. Lambrakis P, Rushworth GF, Adamson J, Leslie SJ: **Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients.** *Therapeutic advances in drug safety* 2011, **2**(6):263-270.

106. Hope AP, Woessner KA, Simon RA, Stevenson DD: **Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease.** *Journal of Allergy and Clinical Immunology* 2009, **123**(2):406-410.
107. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: **The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.** *The New England journal of medicine* 1999, **341**(10):709-717.
108. Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. *The American journal of cardiology* 1990, **66**(21):331-401.
109. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). *The American journal of cardiology* 1990, **66**(10):779-785.
110. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM: **Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.** *The Lancet* 2009, **373**(9665):723-731.
111. Teva Canada Limited: **Teva-captopril.** In: *CA Product Monograph.* Toronto, ON; 2021.
112. Apotex Inc: **Apo-Capto.** In: *Drug Monograph.* Weston, Ontario: Apotex Inc.; 2013.
113. AMICI Pharmaceuticals LLC: **Captopril.** In: *US Product Monograph.* Melville, NY; 2021.
114. Mylan Pharmaceuticals: **Captopril.** In: *US Product Monograph.* Morgantown, WV: Mylan Pharmaceuticals Inc.; 2017.
115. Teva Canada Limited: **Teva-lisinopril.** In: *CA Product Monograph.* Toronto, ON; 2019.
116. Almatica Pharma LLC: **Zestril (lisinopril).** In: *US Product Monograph.* Morristown, NJ; 2020.
117. Sanis Health Inc: **Perindopril.** In: *CA Product Monograph.* Brampton, ON; 2020.
118. Aurobindo Pharma Limited: **Perindopril.** In: *US Product Monograph.* East Windsor, NJ; 2019.
119. Bausch Health Canada Inc: **Altace (ramipril).** In: *CA Product Monograph.* Laval, QC; 2021.
120. Pfizer Laboratories Div Pfizer Inc: **Altace (ramipril).** In: *US Product Monograph.* New York, NY; 2021.
121. BGP Pharma ULC: **Mavik (trandolapril).** In: *CA Product Monograph.* Etobicoke, ON; 2019.
122. A-S Medication Solutions: **Trandolapril.** In: *US Product Monograph.* Baltimore, MD; 2021.
123. Sun Pharma Canada Inc.: **Taro-Valsartan.** In: *CA Product Monograph.* Brampton, ON; 2020.
124. Alembic Pharmaceuticals Inc.: **Valsartan.** In: *US Product Monograph.* Bridgewater, NJ; 2021.
125. PRO DOC LTEE: **Acebutolol.** In: *CA Product Monograph.* Laval, QC; 2019.

126. Amneal Pharmaceuticals of New York LLC: **Acebutolol**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
127. Auro Pharma Inc.: **Auro-carvedilol**. In: *CA Product Monograph*. Woodbridge, ON; 2021.
128. Aurobindo Pharma Limited: **Carvedilol**. In: *US Product Monograph*. East Windsor, NJ; 2021.
129. GlaxoSmithKline LLC: **Coreg CR (carvedilol phosphate capsule extended release)**. In: *US Product Monograph*. Research Triangle Park, NC; 2020.
130. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
131. Dutch Guidelines. [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
132. Teva Canada Limited: **Teva-propranolol**. In: *CA Product Monograph*. Toronto, ON; 2011.
133. Pfizer Canada ULC: **INDERAL-LA (Propranolol Hydrochloride Extended-Release Capsules)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
134. Amneal Pharmaceuticals NY LLC: **Propranolol hydrochloride tablet**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
135. ANI Pharmaceuticals Inc.: **INDERAL LA (propranolol hydrochloride capsule extended release)**. In: *US Product Monograph*. Baudette, MN; 2020.
136. AA Pharma Inc.: **Timolol maleate tablets**. In: *CA Product Monograph*. Vaughan, ON; 2018.
137. Trigen Laboratories LLC: **Timolol maleate tablet**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
138. Upjohn Canada ULC: **Lipitor (atorvastatin)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
139. Parke-Davis Div of Pfizer Inc: **Lipitor (atorvastatin)**. In: *US Product Monograph*. New York, NY; 2020.
140. So D: **Post-myocardial Infarction**. In: *Therapeutics*. Ottawa, Ontario: Canadian Pharmacists Association; 2017.
141. AstraZeneca Canada Inc: **Crestor (rosuvastatin)**. In: *CA Product Monograph*. Mississauga, ON; 2020.
142. AstraZeneca Pharmaceuticals LP: **Crestor (rosuvastatin)**. In: *US Product Monograph*. Wilmington, DE; 2020.
143. Sanofi-aventis Canada Inc: **Nitrolingual Pumpspray (nitroglycerin sublingual spray)**. In: *CA Product Monograph*. Laval, QC; 2021.
144. Evus Pharmaceuticals LLC: **Nitromist (nitroglycerin aerosol)**. In: *US Product Monograph*. Scottsdale, AZ; 2020.

145. Division of Nephrology & Hypertension: **Adult Drug Book**. In: Louisville, KY: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
146. Pharmascience Inc.: **ASA (Acetylsalicylic Acid Delayed-release Tablets)**. In: *CA Product Monograph*. Montreal, QC; 2021.
147. NewHavenPharmaceuticals: **Durlaza (ASA)**. In: *USA Product Monograph*. North Haven, CT: New Haven Pharmaceuticals, Inc.; 2015.
148. sanofi-aventis Canada Inc.: **Plavix (clopidogrel)**. In: *CA Product Monograph*. Laval, QC; 2020.
149. Sun Pharmaceutical Industries Inc.: **Clopidogrel bisulfate**. In: *US Product Monograph*. Cranbury, NJ; 2021.
150. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR *et al*: **Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update**. *Clinical pharmacology and therapeutics* 2013, **94**(3):317-323.
151. AstraZeneca Canada Inc.: **Brilinta (clopidogrel)**. In: *CA Product Monograph*. Mississauga, ON; 2020.
152. AstraZeneca Pharmaceuticals LP: **Brilinta (ticagrelor)**. In: *US Product Monograph*. Wilmington, DE; 2021.
153. JAMP Pharma Corporation: **JAMP prasugrel**. In: *CA Product Monograph*. Boucherville, QC; 2020.
154. Eli Lilly and Company: **Effient (prasugrel)**. In: *US Product Monograph*. Indianapolis, IN; 2021.
155. Upjohn Canada ULC: **Inspra (eplerenone)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
156. Pfizer Inc: **Inspra (eplerenone)**. In: *US Product Monograph*. NY, NY: G.D. Searle LLC; 2018.
157. Dutch guidelines August 2020 update  
[\[https://api.pharmgkb.org/v1/download/file/attachment/DPWG\\_August\\_2020.pdf\]](https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf)
158. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM *et al*: **The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update**. *Clinical pharmacology and therapeutics* 2014, **96**(4):423-428.
159. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y *et al*: **Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics**. *Clinical pharmacology and therapeutics* 2003, **73**(6):554-565.
160. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ *et al*: **High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)**. *Pharmacogenetics* 2004, **14**(7):429-440.
161. Mwinyi J, John A, Bauer S, Roots I, Gerloff T: **Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics**. *Clinical pharmacology and therapeutics* 2004, **75**(5):415-421.

162. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: **Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype \*17.** *Pharmacogenetics and genomics* 2005, **15**(5):303-309.
163. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J *et al*: **An association study of 43 SNPs in 16 candidate genes with atorvastatin response.** *The pharmacogenomics journal* 2005, **5**(6):352-358.
164. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: **Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.** *Clinical pharmacology and therapeutics* 2006, **79**(5):419-426.
165. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivisto KT, Neuvonen PJ, Niemi M: **Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.** *British journal of clinical pharmacology* 2006, **61**(6):706-715.
166. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY *et al*: **SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.** *British journal of clinical pharmacology* 2007, **64**(3):346-352.
167. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, Kim RB: **Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.** *Pharmacogenetics and genomics* 2007, **17**(8):647-656.
168. Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M: **Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.** *Pharmacogenetics and genomics* 2008, **18**(10):921-926.
169. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: **The SLCO1B1\*5 genetic variant is associated with statin-induced side effects.** *Journal of the American College of Cardiology* 2009, **54**(17):1609-1616.
170. Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I: **Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic information on SLCO1B1 and ABCC2 polymorphisms.** *Journal of clinical pharmacology* 2009, **49**(11):1309-1317.
171. Martin NG, Li KW, Murray H, Putt W, Packard CJ, Humphries SE: **The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.** *British journal of clinical pharmacology* 2012, **73**(2):303-306.
172. Li Y, Sabatine MS, Tong CH, Ford I, Kirchgessner TG, Packard CJ, Robertson M, Rowland CM, Bare LA, Shepherd J *et al*: **Genetic variants in the KIF6 region and coronary event reduction from statin therapy.** *Human genetics* 2011, **129**(1):17-23.
173. Iakoubova OA, Robertson M, Tong CH, Rowland CM, Catanese JJ, Blauw GJ, Jukema JW, Murphy MB, Devlin JJ, Ford I *et al*: **KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.** *European journal of cardiovascular prevention and rehabilitation*

: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2010, **17**(4):455-461.

174. Shiffman D, Sabatine MS, Louie JZ, Kirchgessner TG, Iakoubova OA, Campos H, Devlin JJ, Sacks FM: **Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial.** *The American journal of cardiology* 2010, **105**(9):1300-1305.
175. Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ *et al*: **Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.** *Journal of the American College of Cardiology* 2008, **51**(4):435-443.
176. Chasman DI, Posada D, Subrahmanyam L, Cook NR, Stanton VP, Jr., Ridker PM: **Pharmacogenetic study of statin therapy and cholesterol reduction.** *Jama* 2004, **291**(23):2821-2827.
177. Wan Z, Wang G, Li T, Xu B, Pei Q, Peng Y, Sun H, Cheng L, Zeng Y, Yang G *et al*: **Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.** *The Journal of pharmacology and experimental therapeutics* 2015, **354**(3):310-315.
178. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ: **Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?** *European journal of clinical pharmacology* 2015, **71**(3):341-355.
179. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ: **Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.** *European journal of clinical pharmacology* 2015, **71**(3):329-340.
180. Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B: **Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.** *Pharmacogenomics* 2013, **14**(11):1283-1294.
181. DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ *et al*: **Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.** *Circulation Cardiovascular genetics* 2013, **6**(4):400-408.
182. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM: **Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.** *Circulation Cardiovascular genetics* 2012, **5**(2):257-264.
183. Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, Tsui TK, Ko GT, Baum L, Tam LS *et al*: **Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.** *Pharmacogenetics and genomics* 2010, **20**(10):634-637.
184. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, Flather MD *et al*: **Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.** *Circulation Cardiovascular genetics* 2010, **3**(3):276-285.

185. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK: **ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.** *Clinical pharmacology and therapeutics* 2010, **87**(5):558-562.
186. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M: **ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.** *Clinical pharmacology and therapeutics* 2009, **86**(2):197-203.
187. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J *et al*: **Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.** *Clinica chimica acta; international journal of clinical chemistry* 2006, **373**(1-2):99-103.
188. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM: **Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.** *Am Heart J* 2013, **165**(6):1008-1014.
189. Soko ND, Chimusa E, Masimirembwa C, Dandara C: **An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.** *The pharmacogenomics journal* 2019, **19**(3):240-248.
190. Hua S, Ma C, Zhang J, Li J, Wu W, Xu N, Luo G, Zhao J: **Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects.** *Front Pharmacol* 2018, **9**:352.
191. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, Hovingh GK, Kastelein JJ: **Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.** *Circulation Cardiovascular genetics* 2009, **2**(2):173-181.
192. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS: **Identification of genetic variants associated with response to statin therapy.** *Arterioscler Thromb Vasc Biol* 2009, **29**(9):1310-1315.
193. Puccetti L, Ciani F, Auteri A: **Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.** *Atherosclerosis* 2010, **211**(1):28-29.
194. Marcianti KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H *et al*: **Cerivastatin, genetic variants, and the risk of rhabdomyolysis.** *Pharmacogenetics and genomics* 2011, **21**(5):280-288.
195. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, Rieder MJ, Simon JA, Hulley SB, Waters D *et al*: **Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.** *Circulation* 2008, **117**(12):1537-1544.
196. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D *et al*: **A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.** *Nature* 2013, **502**(7471):377-380.

197. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: **Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.** *Pharmacogenomics* 2009, **10**(11):1743-1751.
198. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH: **The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.** *Clinical pharmacology and therapeutics* 2005, **78**(5):551-558.
199. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, Palmer CN, Mukhopadhyay S: **Tailored second-line therapy in asthmatic children with the Arg(16) genotype.** *Clinical science (London, England : 1979)* 2013, **124**(8):521-528.
200. Luzum JA, Theusch E, Taylor KD, Wang A, Sadee W, Binkley PF, Krauss RM, Medina MW, Kitzmiller JP: **Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.** *J Cardiovasc Pharmacol* 2015, **66**(1):80-85.
201. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA: **Genetic determinants of statin intolerance.** *Lipids in health and disease* 2007, **6**:7.
202. de Keyser CE, Eijgelsheim M, Hofman A, Sijbrands EJ, Maitland-van der Zee AH, van Duijn CM, Uitterlinden AG, Witteman JC, Ch Stricker BH: **Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study.** *The pharmacogenomics journal* 2011, **11**(1):72-80.
203. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN: **Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.** *Clinical pharmacology and therapeutics* 2011, **89**(2):210-216.
204. Donnelly LA, van Zuydam NR, Zhou K, Tavendale R, Carr F, Maitland-van der Zee AH, Leusink M, de Boer A, Doevendans PA, Asselbergs FW *et al*: **Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.** *Pharmacogenetics and genomics* 2013, **23**(10):518-525.
205. de Keyser CE, Peters BJ, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, Verstuyft C, Hofman A, Maitland-van der Zee AH, Stricker BH: **The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.** *Pharmacogenetics and genomics* 2014, **24**(1):43-51.
206. Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, Chasman DI, Zhou K, Arsenault BJ, Donnelly LA *et al*: **Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.** *Nat Commun* 2014, **5**:5068.
207. Leusink M, Maitland-van der Zee AH, Ding B, Drenos F, van Iperen EP, Warren HR, Caulfield MJ, Cupples LA, Cushman M, Hingorani AD *et al*: **A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering.** *Pharmacogenomics* 2016, **17**(6):583-591.



208. Wei WQ, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N *et al*: **LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.** *Circulation* 2018, **138**(17):1839-1849.
209. Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, Velez Edwards DR, Wei WQ, Teixeira PL, Bastarache L *et al*: **A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough.** *The pharmacogenomics journal* 2016, **16**(3):231-237.
210. Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, Yue QY, Magnusson PK, Wadelius C, Eriksson N *et al*: **Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.** *Pharmacogenomics* 2017, **18**(3):201-213.
211. Poulussen FCP, Peters BJ, Hua KH, Houthuizen P, Grouls RJ, Deenen MJ: **The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.** *Pharmacogenetics and genomics* 2019, **29**(7):179-182.
212. Li S, Lin H, Sun W, Wang Y, Ding Y, Zhao H, Liu S: **A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol.** *Int J Clin Pharmacol Ther* 2017, **55**(6):483-492.
213. Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G, Rytting E, Thummel K, Kelly EJ, Risler L *et al*: **Pharmacokinetics of metoprolol during pregnancy and lactation.** *Journal of clinical pharmacology* 2016, **56**(5):581-589.
214. Batty JA, Hall AS, White HL, Wikstrand J, de Boer RA, van Veldhuisen DJ, van der Harst P, Waagstein F, Hjalmarsen A, Kjekshus J *et al*: **An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.** *Clinical pharmacology and therapeutics* 2014, **95**(3):321-330.
215. Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Skaar TC, Chapman AB, Gums JG, Turner ST, Gong Y *et al*: **Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.** *Clinical pharmacology and therapeutics* 2014, **96**(2):175-181.
216. Blake CM, Kharasch ED, Schwab M, Nagele P: **A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.** *Clinical pharmacology and therapeutics* 2013, **94**(3):394-399.
217. Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH: **Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.** *Clinical pharmacology and therapeutics* 2009, **85**(1):45-50.
218. Jin SK, Chung HJ, Chung MW, Kim JI, Kang JH, Woo SW, Bang S, Lee SH, Lee HJ, Roh J: **Influence of CYP2D6\*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.** *Journal of clinical pharmacy and therapeutics* 2008, **33**(5):567-573.
219. Zineh I, Beitelshes AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA: **Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.** *Clinical pharmacology and therapeutics* 2004, **76**(6):536-544.

220. Taguchi M, Nozawa T, Mizumaki K, Inoue H, Tahara K, Takesono C, Hashimoto Y: **Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.** *Biological & pharmaceutical bulletin* 2004, **27**(10):1642-1648.
221. Yang YY, Lin HC, Lin MW, Chu CJ, Lee FY, Hou MC, Lee SD, Lee WP, Liu TT, Jap TS: **Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites.** *Clinical science (London, England : 1979)* 2011, **121**(11):509-521.
222. Volkan-Salanci B, Dagdelen S, Alikasifoglu M, Erbas T, Hayran M, Erbas B: **Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus.** *Journal of the renin-angiotensin-aldosterone system : JRAAS* 2009, **10**(1):41-50.
223. Kanazawa H, Hirata K, Yoshikawa J: **Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study.** *Thorax* 2003, **58**(7):629-631.
224. O'Toole L, Stewart M, Padfield P, Channer K: **Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure.** *J Cardiovasc Pharmacol* 1998, **32**(6):988-994.
225. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, Cambien F, Parving HH: **Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.** *Kidney international* 1998, **53**(4):1002-1006.
226. Mizuiri S, Hemmi H, Inoue A, Takano M, Kadomatsu S, Tanimoto H, Tanegashima M, Hayashi I, Fushimi T, Hasegawa A: **Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism.** *Nephron* 1997, **75**(3):310-314.
227. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: **Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.** *BMJ (Clinical research ed)* 1996, **313**(7057):591-594.
228. Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M: **Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.** *Biological & pharmaceutical bulletin* 2007, **30**(3):537-542.
229. Honda M, Ogura Y, Toyoda W, Taguchi M, Nozawa T, Inoue H, Hashimoto Y: **Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.** *Biological & pharmaceutical bulletin* 2006, **29**(4):772-778.
230. Luzum JA, Sweet KM, Binkley PF, Schmidlen TJ, Jarvis JP, Christman MF, Sadee W, Kitzmiller JP: **CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.** *Pharmaceutical research* 2017, **34**(8):1615-1625.
231. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG: **Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.** *Clinical pharmacology and therapeutics* 2005, **77**(6):486-494.

232. Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A: **Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant.** *The British journal of dermatology* 2006, **154**(2):256-260.
233. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A: **Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma.** *The Journal of allergy and clinical immunology* 2004, **113**(4):771-775.
234. Lee HY, Lee JW, Lee KW, Park MH, Park HS: **The HLA allele marker for differentiating ASA hypersensitivity phenotypes.** *Allergy* 2009, **64**(9):1385-1387.
235. Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, Park HS: **HLA association in aspirin-intolerant asthma: DPB1\*0301 as a strong marker in a Korean population.** *The Journal of allergy and clinical immunology* 2004, **113**(3):562-564.
236. Dekker JW, Nizankowska E, Schmitz-Schumann M, Pile K, Bochenek G, Dyczek A, Cookson WO, Szczeklik A: **Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes.** *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 1997, **27**(5):574-577.
237. Matsubara Y, Murata M, Watanabe G, Ikeda Y: **Enhancing effect of the (145)Met-allele of GPIb alpha on platelet sensitivity to aspirin under high-shear conditions.** *Thrombosis research* 2008, **123**(2):331-335.
238. Fujiwara T, Ikeda M, Esumi K, Fujita TD, Kono M, Tokushige H, Hatoyama T, Maeda T, Asai T, Ogawa T *et al*: **Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity.** *The pharmacogenomics journal* 2007, **7**(6):395-403.
239. Lepantalo A, Mikkelsen J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R: **Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.** *Thrombosis and haemostasis* 2006, **95**(2):253-259.
240. Verschuren JJ, Boden H, Wessels JA, van der Hoeven BL, Trompet S, Heijmans BT, Putter H, Guchelaar HJ, Schali J, Jukema JW: **Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.** *International journal of cardiology* 2013, **167**(6):2882-2888.
241. Goodman T, Ferro A, Sharma P: **Pharmacogenetics of aspirin resistance: a comprehensive systematic review.** *British journal of clinical pharmacology* 2008, **66**(2):222-232.
242. Ulehlova J, Slavik L, Kucerova J, Krcova V, Vaclavik J, Indrak K: **Genetic polymorphisms of platelet receptors in patients with acute myocardial infarction and resistance to antiplatelet therapy.** *Genet Test Mol Biomarkers* 2014, **18**(9):599-604.
243. Sorich MJ, Rowland A, McKinnon RA, Wiese MD: **CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.** *Circulation Cardiovascular genetics* 2014, **7**(6):895-902.
244. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC, Zhao X *et al*: **Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.** *Circulation* 2017, **135**(1):21-33.

245. Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US *et al*: **The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.** *Pharmacogenetics and genomics* 2013, **23**(1):1-8.
246. Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M: **Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.** *Clinical pharmacology and therapeutics* 2015, **97**(6):650-658.
247. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Rossi JS, Clarke M, Cicci JD, Cavallari LH, Weck KE *et al*: **Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.** *Genet Med* 2019.
248. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF: **Cytochrome P450 2C19\*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.** *The pharmacogenomics journal* 2011, **11**(3):199-206.
249. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W: **Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.** *Arch Cardiovasc Dis* 2013, **106**(10):517-527.
250. Kheiri B, Osman M, Abdalla A, Haykal T, Pandrangi PV, Chahine A, Ahmed S, Osman K, Bachuwa G, Hassan M *et al*: **CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.** *Catheter Cardiovasc Interv* 2019, **93**(7):1246-1252.
251. Williams AK, Klein MD, Martin J, Weck KE, Rossi JS, Stouffer GA, Lee CR: **CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.** *Circ Genom Precis Med* 2019, **12**(2):e002441.
252. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, Masumoto H, Okutani Y: **Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study.** *The pharmacogenomics journal* 2008, **8**(1):29-33.